Preserves access to affordable drugs
Summary
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
Bill status
passed
3 of 5 stages cleared
Introduction
Jan 2025
Committee Review
Feb 2026
Senate Passage
Feb 2026
Assembly Passage
Governor
Introduced Jan 24, 2025
Last action Feb 24, 2026
Floor votes · Senate May 20, 2025
How they voted
41–20
Passed · 1 other
Total votes 62
May 20, 2025
D
Democratic40
100% Yea
R
Republican22
90% Nay
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
17
Key actions
2
Committee
5
Feb 24, 2026
Committee
REFERRED TO HEALTH
lower
Feb 24, 2026
Upper · Passed
PASSED SENATE
upper
Jan 7, 2026
Committee
REFERRED TO HEALTH
upper
May 20, 2025
Committee
REFERRED TO HEALTH
lower
May 20, 2025
Upper · Passed
PASSED SENATE
upper
Mar 4, 2025
Committee
REPORTED AND COMMITTED TO FINANCE
upper
Jan 24, 2025
Committee
REFERRED TO HEALTH
upper
1 primary · 6 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about S 3203
Scope: NY
Hi! I can help you understand S 3203. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline